EHA25: The Present and Future of T cell-based Immunotherapy

A selection of videos from EHA25 are now available on the European Immunotherapy Net. In this article, presentations covering the increasingly growing field of T cell-based immunotherapy are shared.

In her lecture, Chiara Bonini provides an overview of the present and future role of TCR-transduced T cell for immunotherapy of hematological malignancies, spanning from the initial and more simple approaches including DLI and in vitro expanded T cells, to the present CAR-T technologies, and the most innovative treatments that can currently be envisaged, such as patient-specific synthetic T cells. 

Coming back to the present, browse some of the oral presentations from the EHA25 scientific program, reporting updated results from CAR-T clinical trials in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia. 

Click on the links below to play the sessions. Stay tuned for more relevant content from EHA25!

Chiara Bonini - Future role of TCR transduced T cells

Valentín Ortiz-Maldonado - CART19-BE-01: A European Academic Trial On The Administration Of Ari-0001 Cells In Patients With Acute Lymphoblastic Leukemia And Other Cd19+ Lymphoproliferative Disorders 

Caron Jacobson - Interim Analysis Of Zuma-5: A Phase 2 Study Of Axicabtagene Ciloleucel (Axi-Cel) In Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma 

Mingzhi Zhang - First-In-Human Clinical Trial Of The Autologous Cd7-Cart Cells For Patients With Relapsed And Refractory Acute Lymphoblastic Leukemia/Lymphoma


Last Updated on Thursday 17 December 2020.